Related Experiment Video
Updated: May 4, 2026
05:05
Preparation of Mesh-Shaped Engineered Cardiac Tissues Derived from Human iPS Cells for In Vivo Myocardial Repair
Published on: June 9, 2020
4.6K
Engineered cardiac patches from hiPSC-derived cardiomyocytes.
Jonas Jawad1, Mohammad Z Khan1, Tamer Jabsheh1
1California University of Science and Medicine, 1501 Violet St, Colton, CA, 92324, USA.
Stem Cell Research & Therapy
|May 2, 2026
Summary
Engineered cardiac patches using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) show promise for heart failure treatment. Early trials demonstrate safety and efficacy, though challenges in immune compatibility and manufacturing remain.
Area of Science:
- Regenerative Medicine
- Cardiology
- Biomaterials Engineering
Background:
- Heart failure has limited myocardial regeneration capacity.
- Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer scalable, adaptable therapeutic potential.
- Engineered cardiac patches deliver organized myocardium to repair injured hearts, overcoming cell injection limitations.
Purpose of the Study:
- To review advancements in engineered hiPSC-CM cardiac patches for heart failure.
- To evaluate preclinical and early clinical evidence of their efficacy and safety.
- To identify key challenges and potential solutions for clinical translation.
Main Methods:
- Synthesized evidence from 2010-2025, including preclinical models (rodent, porcine, non-human primate) and clinical trials.
- Highlighted progress in hiPSC-CM maturation, vascularization, and scaffold engineering.
- Examined translational paradigms: paracrine support vs. remuscularization.
Main Results:
- Preclinical studies show improved graft survival (5-15%), vascularization, electrical coupling, and cardiac function.
- Large animal models demonstrated durable integration and improved hemodynamics with clinically relevant patch sizes.
- Early human trials confirm feasibility and safety, with preliminary efficacy in improving ejection fraction and NYHA class.
Conclusions:
- Engineered hiPSC-CM cardiac patches are a promising regenerative cardiology frontier.
- Technical feasibility and functional benefits are evident, but immune compatibility, arrhythmia risk, and manufacturing scalability require resolution.
- Addressing these challenges could establish cardiac patches as a transformative heart failure therapy.
